surmount 3 tirzepatide Diabetes Dialogue: SURMOUNT-3 and -4 Inform Use of in Obesity Tirzepatide after intensive lifestyle intervention

Description

doi: 10.1073/pnas.0600655103

A hard fixed mass , especially if it is off to one side, needs careful evaluation

Switching between semaglutide and tirzepatide is increasingly common, especially for researchers who have plateaued on one compound and want to explore whether a dual agonist (GLP-1/GIP) provides additional benefits

Critical Safety Information Black Box Warning: Semaglutide (specifically brand names like Ozempic/Wegovy) carries a boxed warning regarding the risk of thyroid C-cell tumors

If you experience any combination of fatigue, neurological symptoms, or unusual weakness after starting semaglutide, report these to your healthcare provider promptly rather than attributing them solely to weight loss or diet changes